BioMimetic Pharmaceuticals and
Selected Abstract
BioMimetic Pharmaceuticals and ZymoGenetics Sign Second Licensing Agreement for Clinical Development and Commercialization of PDGF.
Business Editors and Health/Medical Writers FRANKLIN, Tenn. & SEATTLEBUSINESS WIREFeb. 6, 2003 BioMimetic to Develop Novel Products for Orthopaedic Procedures, Treatment of Bone Defects and Osteoporosis BioMimetic Pharmaceuticals, Inc. (BMPI) and ZymoGenetics, Inc. (Nasdaq:ZGEN) announced today ... February 6, 2003; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
BioMimetic Pharmaceuticals and ZymoGenetics Sign Second Licensing Agreement for Clinical Development and Commercialization of PDGF.
2.
Ann F. Hanham Promoted to Managing Director at Burrill & Company; San Francisco-Based Life Sciences Merchant Bank Adds New Managing Director.
3.
Memphis, Tenn., Biotech Conference Unites Researchers, Scientists, Investors.
|
